Phase II ALS Clinical Trial With BrainStorm Cell Therapeutics' NurOwn(TM) to Be Expanded to a Third Premiere U.S. Clinical Site

Phase II ALS Clinical Trial With BrainStorm Cell Therapeutics' NurOwn(TM) to Be 
Expanded to a Third Premiere U.S. Clinical Site 
NEW YORK, NY and PETACH TIKVAH, ISRAEL -- (Marketwire) -- 03/18/13 --
 BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of
adult stem cell technologies for neurodegenerative diseases,
announced today that Mayo Clinic in Rochester, Minnesota has entered
into a Memorandum of Understanding with the intent to conduct a Phase
II clinical trial of NurOwn(TM) in amyotrophic lateral sclerosis
(ALS), more commonly known as Lou Gehrig's Disease. Mayo Clinic is
the third premiere U.S. clinical site to sign a memorandum of
understanding with the Company, following the University of
Massachusetts, and Massachusetts General Hospital (MGH). 
"We are pleased that Mayo Clinic, a world renowned and prominent
clinical center, will be conducting the Phase II clinical trial of
NurOwn in ALS," said Alon Natanson, Chief Executive Officer of
BrainStorm. "It is very encouraging that top tier U.S. centers of
excellence have expressed an interest in playing a leading part in
our research." The Principal Investigator of this study at Mayo
Clinic is Anthony Windebank, M.D., Professor of Neurology. 
Initial results from Phase I studies in ALS suggest that patients
with ALS experience a positive clinical outcome after treatment with
NurOwn. The Company is planning to enroll patients into clinical
trials at Mayo Clinic, the University of Massachusetts, and
Massachusetts General Hospital as early as the second half of 2013 to
further evaluate the effects of treatment with NurOwn in ALS. 
"This is another step forward in finding a potentially effective
treatment option for patients with ALS," added Mr. Natanson.
"BrainStorm has presented encouraging preliminary data on NurOwn at
many scientific conferences. This week, we will present some of our
breakthrough final Phase I data at the most prestigious world
neurology meeting, the Annual Meeting of the American Academy of
Neurology, on Wednesday, March 20th." 
About NurOwn(TM)
 NurOwn is an autologous, adult stem cell therapy
technology that differentiates bone marrow-derived mesenchymal stem
cells (MSC) into specialized, neuron-supporting cells. These
neuron-supporting cells (known as "MSC-NTF" cells) secrete
neurotrophic, or nerve-growth, factors for PROTECTION of existing
motor neurons, PROMOTION of motor neuron growth, and RE-ESTABLISHMENT
of nerve-muscle interaction. The ability to differentiate mesenchymal
stem cells into MSC-NTF cells, and confirmation of their activity and
potency before transplantation, makes NurOwn a first-of-its-kind
approach for treating neurodegenerative diseases. More information
about NurOwn(TM) can be found at 
About BrainStorm Cell Therapeutics, Inc.
 BrainStorm Cell
Therapeutics Inc. is a biotechnology company engaged in the
development of first-of-its-kind adult stem cell therapies derived
from autologous bone marrow cells for the treatment of
neurodegenerative diseases. The Company holds the rights to develop
and commercialize its NurOwn technology through an exclusive,
worldwide licensing agreement with Ramot, the technology transfer
company of Tel Aviv University. For more information, visit the
company's website at 
Safe Harbor Statement - Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended to
identify these forward-looking statements. The potential risks and
uncertainties include, without limitation, risks associated with
BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain
required regulatory approvals; and other factors detailed in
BrainStorm's annual report on Form 10-K and quarterly reports on Form
10-Q available at These factors should be
considered carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press
release. We do not assume any obligation to update forward-looking
statements to reflect actual results or assumptions if circumstances
or management's beliefs, expectations or opinions should change,
unless otherwise required by law. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. 
BrainStorm Cell Therapeutics Inc. 
Mr. Alon Natanson
Phone: +972-3-9236384  
LifeSci Advisors, LLC
Michael Rice
Founding Partner
Press spacebar to pause and continue. Press esc to stop.